Maxwell Biosciences
Founded in 2016, Maxwell Biosciences is a preclinical stage biotechnology company focused on developing innovative therapeutics targeting viruses, bacteria, fungi, and biofilm formations. Utilizing a unique drug-discovery platform, the company aims to create affordable and effective health solutions to combat infectious diseases and enhance healthspan.
Maxwell Biosciences
Austin, Texas, United States of America
What We Do
MXB-22,510
A lead drug candidate with the potential to replace many antifungals and antibiotics, providing frontline therapy for various viral infections.
Claromer® Drug Candidates
A family of drug candidates shown to be highly potent against a broad spectrum of pathogens, including AMR bacteria, fungi, and viruses such as Ebola.
News & Updates
Maxwell Biosciences has been awarded nearly $3 million from MTEC to support its research and development efforts.
The company has entered a second Cooperative Research and Development Agreement with USAMRIID to test its Claromer compounds.
CEO J. Scotch McClure has been recognized as one of the top 25 executives in the biotechnology sector.
The company reported promising results from a study showing the effectiveness of its Claromer compound against the Ebola virus.
Maxwell has entered a CRADA with USAMRIID to explore the potential of its Claromer compounds against various viral pathogens.